- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- Extent
-
1 Online-Ressource.
- Language
-
Englisch
- Bibliographic citation
-
A phenocopy signature of TP53 loss predicts response to chemotherapy ; volume:8 ; number:1 ; day:2 ; month:10 ; year:2024 ; pages:1-10 ; date:12.2024
npj precision oncology ; 8, Heft 1 (2.10.2024), 1-10, 12.2024
- Creator
-
Bakhtiar, Hamza
Sharifi, Marina N.
Helzer, Kyle T.
Shi, Yue
Bootsma, Matthew L.
Shang, Tianfu A.
Chrostek, Matthew R.
Berg, Tracy J.
Carson Callahan, S.
Carreno, Viridiana
Blitzer, Grace C.
West, Malinda T.
O’Regan, Ruth M.
Wisinski, Kari B.
Sjöström, Martin
Zhao, Shuang G.
- Contributor
-
SpringerLink (Online service)
- DOI
-
10.1038/s41698-024-00722-7
- URN
-
urn:nbn:de:101:1-2412192106215.487303043397
- Rights
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
-
15.08.2025, 7:20 AM CEST
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
- Bakhtiar, Hamza
- Sharifi, Marina N.
- Helzer, Kyle T.
- Shi, Yue
- Bootsma, Matthew L.
- Shang, Tianfu A.
- Chrostek, Matthew R.
- Berg, Tracy J.
- Carson Callahan, S.
- Carreno, Viridiana
- Blitzer, Grace C.
- West, Malinda T.
- O’Regan, Ruth M.
- Wisinski, Kari B.
- Sjöström, Martin
- Zhao, Shuang G.
- SpringerLink (Online service)
Other Objects (12)
Convergent TP53 loss and evolvability in cancer
The E2F4 prognostic signature predicts pathological response to neoadjuvant chemotherapy in breast cancer patients
Non-chemotherapy adjuvant agents in TP53 mutant Ewing sarcoma
Impact of clonal TP53 mutations with loss of heterozygosity on adjuvant chemotherapy and immunotherapy in gastric cancer
A two-microRNA-based signature predicts first-line chemotherapy outcomes in advanced colorectal cancer patients
A pseudogene-signature in glioma predicts survival
Skeletal muscle loss during neoadjuvant chemotherapy predicts poor prognosis in patients with breast cancer
Prevalence of Allelic Loss at TP53 in Endometrial Carcinomas
A Minimal lncRNA-mRNA Signature Predicts Sensitivity to Neoadjuvant Chemotherapy in Triple-Negative Breast Cancer
A novel methylation signature predicts radiotherapy sensitivity in glioma
Pretreatment gut microbiome predicts chemotherapy-related bloodstream infection
KRAS and TP53 co-mutation predicts benefit of immune checkpoint blockade in lung adenocarcinoma
Convergent TP53 loss and evolvability in cancer
The E2F4 prognostic signature predicts pathological response to neoadjuvant chemotherapy in breast cancer patients
Non-chemotherapy adjuvant agents in TP53 mutant Ewing sarcoma
Impact of clonal TP53 mutations with loss of heterozygosity on adjuvant chemotherapy and immunotherapy in gastric cancer
A two-microRNA-based signature predicts first-line chemotherapy outcomes in advanced colorectal cancer patients
A pseudogene-signature in glioma predicts survival
Skeletal muscle loss during neoadjuvant chemotherapy predicts poor prognosis in patients with breast cancer
Prevalence of Allelic Loss at TP53 in Endometrial Carcinomas
A Minimal lncRNA-mRNA Signature Predicts Sensitivity to Neoadjuvant Chemotherapy in Triple-Negative Breast Cancer
A novel methylation signature predicts radiotherapy sensitivity in glioma
Pretreatment gut microbiome predicts chemotherapy-related bloodstream infection
KRAS and TP53 co-mutation predicts benefit of immune checkpoint blockade in lung adenocarcinoma
Convergent TP53 loss and evolvability in cancer
The E2F4 prognostic signature predicts pathological response to neoadjuvant chemotherapy in breast cancer patients
Non-chemotherapy adjuvant agents in TP53 mutant Ewing sarcoma
Impact of clonal TP53 mutations with loss of heterozygosity on adjuvant chemotherapy and immunotherapy in gastric cancer
A two-microRNA-based signature predicts first-line chemotherapy outcomes in advanced colorectal cancer patients
A pseudogene-signature in glioma predicts survival
Skeletal muscle loss during neoadjuvant chemotherapy predicts poor prognosis in patients with breast cancer
Prevalence of Allelic Loss at TP53 in Endometrial Carcinomas
A Minimal lncRNA-mRNA Signature Predicts Sensitivity to Neoadjuvant Chemotherapy in Triple-Negative Breast Cancer
A novel methylation signature predicts radiotherapy sensitivity in glioma
Pretreatment gut microbiome predicts chemotherapy-related bloodstream infection